Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;14(4):228-232.
doi: 10.5114/pg.2019.90249. Epub 2019 Dec 20.

Inflammatory bowel disease - one entity with many molecular faces

Sylwia Szymańska  1 , Malgorzata Matuszczyk  2 , Magdalena Osuch  3 , Monika Meglicka  2 , Edyta Szymanska  2 , Joanna Bierła  1 , Jaroslaw Kierkuś  2
Affiliations
Review

Inflammatory bowel disease - one entity with many molecular faces

Sylwia Szymańska et al. Prz Gastroenterol. 2019.

Abstract

Inflammatory bowel disease (IBD) is a heterogenous group of chronic inflammations in the gastrointestinal tract, which traditionally consists of two types: Crohn's disease and ulcerative colitis. They differ when it comes to clinical, endoscopic, and histopathological changes. The exact aetiology of IBD has not been fully comprehended, but what is known so far is that the aetiopathogenesis of the disease is compound. Many articles have been written on the cellular/molecular background of IBD. Based on various molecular pathways, new forms of the disease have been discovered, including very early-onset IBD (VEO-IBD) or IBD coexisting with primary sclerosing cholangitis. The aim of this article is to present the molecular mechanisms leading to IBD, focusing on new forms of this disorder.

Keywords: Crohn’s disease; genetics; inflammatory bowel disease; molecular pathways; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Basic diagram of pathogenetic factors and their molecular pathways in patients with IBD
See this image and copyright information in PMC

References

    1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205. - PubMed
    1. Xavier R, Podolsky D. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–34. - PubMed
    1. Zuo T. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247. - PMC - PubMed
    1. Guehler SR, Finch RJ, Bluestone JA, Barrett TA. Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes. J Immunol. 1998;160:5341–6. - PubMed
    1. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2000;55:205–11. - PMC - PubMed